Analysts said the deal shows Roche’s long-term strategy for its sequencing technology is “a clinical box for running NGS kits ...

The partnership will expedite the availability of Freenome's tests in markets outside the U.S, according to the company.

Roche will receive rights to at least 1 billion lateral flow tests annually from Sapphiros as well as access to the company's future molecular testing technology.

Freenome has announced a strategic agreement with Roche aimed at commercialising its cancer screening technology outside the ...

Exact Sciences stock has recently seen its consensus analyst price target climb significantly, from around $70 to $82.10. This reflects renewed confidence in the company’s long-term value and ...

Brisbane-based Freenome has locked in a second major partnership for its blood-based cancer screening test, this time with a ...

Freenome, an early cancer detection company developing blood-based screening tests, today announced a strategic collaboration agreement with Roche to commercialize Freenome's cancer screening ...

(MENAFN- GlobeNewsWire - Nasdaq) Key opportunities in the AI clinical genomics interpretation market include the rising demand for precision medicine, wider adoption of AI-powered tools, advancements ...

Roche is forging ahead with plans to seek approval for an eye disease drug candidate despite missing the primary endpoint in one of its phase 3 trials. The Swiss drugmaker ran two identical studies, ...

Elecsys’ approval could help boost the uptake of currently approved Alzheimer’s disease therapies, including Biogen’s Eisai-partnered Leqembi, with CEO Chris Viehbacher recently noting that such ...

Roche Holdings AG (OTC:RHHBY) on Monday outlined its plan to become a leading player in the surging weight-loss drug market, pushing its obesity pipeline farther into late-stage development as it eyes ...